PER 3.53% 8.2¢ percheron therapeutics limited

and a far greater number of patients. FWIW the reason I put back...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 35,755 Posts.
    lightbulb Created with Sketch. 554
    and a far greater number of patients.

    FWIW the reason I put back to Chiasma is really outside of the success or failure or even anything to do with the actual drug it was more about the structure of the deal. Comparatively if ANP is searching for a deal where the party covers the Phase III trial then right there that is say $30M so they are contributing greater than the company is worth at this point just to put the drug through --- what would they want for that ? As obviously ANP doesn't have the funds to do it without another party stepping in. Chiasma got a big figure upfront basically because it reimbursed the already funded phase III the bulk of the deal as with milestones was set at the back end of product in market.

    My bet is if a partner steps in to fund the Phase III trial they will take a big equity stake with it.

    Just me view,
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.2¢
Change
-0.003(3.53%)
Mkt cap ! $85.01M
Open High Low Value Volume
8.5¢ 8.6¢ 8.2¢ $103.7K 1.237M

Buyers (Bids)

No. Vol. Price($)
3 204084 8.2¢
 

Sellers (Offers)

Price($) Vol. No.
8.5¢ 280000 3
View Market Depth
Last trade - 16.10pm 13/11/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.